Radiation Therapy for Locally Advanced Breast Cancer
Conference Objectives: At the completion of the program, participants should be able to:
Review the recent mammographic controversy, the evidence for and against the use of screening mammography in general, the clinical trials supporting the use of mammographic screening and their flaws. Review the data evaluating digital mammographic techniques in breast cancer screening. Review the current recommendations for mammographic screening.
Review and understand the sentinel lymph node procedure, its rationale, and the University of Pennsylvania experience with all variables associated with this procedure, including success rate, predictive value, axillary failure rates, and examine all of these variables in additional subgroups of patients, including patients with larger tumors, patients receiving preoperative chemotherapy, and patients with multifocal and noninvasive tumors.
Review the therapeutic benefit of radiation therapy as adjunctive treatment in patients with locally advanced breast cancers, including long-term disease free and overall survival, patterns of failure, and reductions in long-term morbidity and mortality from such treatment.
Review and understand the technique of ductal lavage, its application in high-risk patients, its potential application in the general population, the predictive value of the findings at ductal lavage, and the data to support this technique as a widely applicable screening devide for women at risk for breast cancer.
Review the international experience to date with trastuzumab in the treatment of metastatic breast cancer, including clinical trials of trastuzumab alone and in combination with various chemotherapeutic agents, the short-term and long-term toxicities of trastuzumab, and the data supporting the use of trastuzumab based on degree of HER-2 overexpression. Review and understanding the various techniques for assaying HER-2 overexpression, and the advantage and limitations of these techniques.
Review the current consensus on adjuvant therapy of breast cancer, including the controversial topics of ovarian ablation in premenopausal women, the application of taxanes in adjuvant therapy, and the international consensus on optimum treatment in all patient subgroups. Review recently developed softward programs, which aid patients and physicians in make rational adjuvant therapy decisions.
Who Should Attend: Surgeons, Medical Oncologists, Radiation Oncologists, Oncology Nurses, Social Workers and all practitioners involved in the treatment of breast cancer.
8:00-8:30 Registration and Sign-In
8:30-8:45 Welcome and Introduction John H. Glick, MD Kevin R. Fox, MD
8:45-9:30 The Mammogram Controversy Revisited: Sorting It All Out - Emily F. Conant, MD
9:30-10:15 Adjuvant Therapy of Breast Cancer: A Novel Approach To An Old Problem - Peter M. Ravdin, MD, PhD
10:15-10:45 Questions and Answers
11:00-11:45 Ductal Lavage for the Detection of Breast Cancer: How It Works and What's the Evidence - Susan M. Domchek, MD
11:45-12:30 The Role of Radiation Therapy in the Treatment of Locally Advanced Breast Cancer: Long Term Follow-Up - Eleanor E.R. Harris, MD
12:30-1:00 Questions and Answers
2:00-2:45 A Review of the Role of Heerceptin in the Treatment of Metastatic Breast Cancer - Charles L. Vogel, MD, FACP,PA
2:45-3:00 The Sentinel Lymph Node Procedure: A Comprehensive Review of the Penn Experience - Brian J. Czerniecki, MD, PhD
Conference Fees: $160.00 for physicians; $95.00 for nurses and other health
care professionals; no fee for faculty, staff or students of the
University of Pennsylvania
Continuing Education: The University of Pennsylvania School of Medicine designates this continuing medical education activity for a maximum of 6 credit hours in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Feb 20, 2012 - In the United States, the use of partial nephrectomy procedures to manage renal masses in patients with renal cell carcinoma increased significantly from 2002 to 2008, according to research published in the March issue of The Journal of Urology.